Advertisement

The Problem of Pulmonary Hypertension in the Potential Cardiac Transplant Recipient

  • J. M. Chen
  • R. E. Michler

Abstract

Despite advances in perioperative management, right-sided circulatory failure (RSCF) remains a significant source of morbidity and mortality early after cardiac transplantation. Perioperative RSCF, while clearly multifactorial in nature, has traditionally been associated with pretransplant pulmonary hypertension, as suggested by elevated pulmonary hemodynamic indices revealed on pretransplant cardiac catheterization. While severely elevated values of such indices represent a contraindication to cardiac transplantation at many centers worldwide, there currently exist no standard guidelines regarding the validity and importance of these preoperative abnormalities for postoperative outcome. The purpose of this chapter is to review the problem of pulmonary hypertension and the potential cardiac transplant recipient - its diagnosis, management and manipulation, and long-term clinical significance.

Keywords

Pulmonary Hypertension Pulmonary Vascular Resistance Cardiac Transplantation Heart Lung Transplant Wood Unit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Griepp RB, Stinson EB, Dong E Jr. Clark DA. Shumway NE. Determinants of operative risk in human heart transplantation. Am J Surg. 1971;122:192–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Bourge RC, Naftel DC, Costanzo-Nordin MR et al. and the Transplant Cardiologists Research Database Group. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. J Heart Lung Transplant. 1993;12:549–62.PubMedGoogle Scholar
  3. 3.
    Erickson KW, Costanzo-Nordin MR, O’Sullivan EJ. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant. 1990;9:526–37.PubMedGoogle Scholar
  4. 4.
    Bourge RC, Kirklin JK, Naftel DC, White C, Mason DA, Epstein AE. Analysis and predictors of pulmonary vascular resistance after cardiac transplantation. J Thorac Cardiovasc Surg. 1991;l0l:432–45.Google Scholar
  5. 5.
    Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988;7:331–336.PubMedGoogle Scholar
  6. 6.
    Murali S, Kormos RL, Uretsky BF et al. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J. 1993;126:896–904.PubMedCrossRefGoogle Scholar
  7. 7.
    Addonizio LH. Gersony WM, Robbins RC et al. Evelated pulmonary vascular resistance and cardiac transplantation. Circulation. 1987;76(Suppl. V):V52–5.PubMedGoogle Scholar
  8. 8.
    Kirklin JK, Naftel DC, McGriffin DC, McVay RF, Blackstone EH, Karp RB. Analysis of morbid events and risk factors for death after cardiac transplantation. J Am Coll Cardiol. 1988;11:917–24.PubMedGoogle Scholar
  9. 9.
    Anguita M, Arizon JM, Valles F et al. Influence of survival after heart transplantation of contraindications seen in transplant recipients. J Heart Lung Transplant. 1992;11:708–15.PubMedGoogle Scholar
  10. 10.
    Bando K, Konishi H, Komatsu K et al. Improved survival following pediatric cardiac transplantation in high-risk patients. Circulation. 1993;88:218–23.Google Scholar
  11. 11.
    Sciolaro C, Cork R, Barkenbush M. Icenogle T, Copeland J. Preoperative hemodynamic data as risk factors for pulmonary infections in cardiac transplantation. J. Heart Transplant. 1988;7:62.Google Scholar
  12. 12.
    Gajarski RJ, Towbin JA, Bricker T et al. Intermediate follow-up of pediatric heart transplant recipients with elevated pulmonary vascular resistance index. J Am Coll Cardiol. 1994;23:1682–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen JM, Levin HR, Michler RE, Prusmack CM, Rose EA, Aaronson KD Reevaluating The Significance of Pulmonary Hypertenstion Prior to Cardiac Transplantation: Determination of Optimal Thresholds and Quantification of the Effect of Reversibility on Perioperative Mortality. (Submitted for Publication).Google Scholar
  14. 14.
    Pierce JC, Cornell RG. Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making. 1993;13:141–51.CrossRefGoogle Scholar
  15. 15.
    Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.PubMedGoogle Scholar
  16. 16.
    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–43.PubMedGoogle Scholar
  17. 17.
    Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high-risk group. J Am Coll Cardiol. 1992;19:48–54.PubMedGoogle Scholar
  18. 18.
    Knapp E, Gmeiner R. Reduction of pulmonary hypertension by nitroprusside. Int J Clin Pharmacol. 1977;15:75–80.Google Scholar
  19. 19.
    Kieler-Jensen N. Milocco I, Ricksten S. Pulmonary vasodilation after heart transplantation. A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant. 1993;12:179–84.PubMedGoogle Scholar
  20. 20.
    Haywood GA, Sneddon JF, Bashir Y, Jennison SH, Gray HH, McKenna WJ. Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure. A good test but a poor therapy. Circulation. 1992;86:896–902.PubMedGoogle Scholar
  21. 21.
    Boiling SF, Deeb GM, Crowley DC, Badelino MM, Bove EL. Prolonged amrinone therapy prior to orthotopic cardiac transplantation in patients with pulmonary hypertension. Transplant Proc. 1988;20(Suppl. 1):753–6.Google Scholar
  22. 22.
    Deeb GM. Bolling SF, Guynn TP, Nicklas JM. Amrinone versus conventional therapy in pulmonary hypertensive patients awaiting cardiac transplantation. Ann Thorac Surg. 1989;48:665–9.PubMedGoogle Scholar
  23. 23.
    Murali S. Uretsky BF, Reddy PS, Tokarczyk TR, Betschart AR. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents. Am Heart J. 1991;122:1375–81.PubMedCrossRefGoogle Scholar
  24. 24.
    Murali S, Uretsky BF, Armitage JM et al. Utility of prostaglandin El in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant. 1992;11:716–23.PubMedGoogle Scholar
  25. 25.
    Iberer F, Wasler A, Tscheliessnigg K, et al. Prostaglandin El-induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation. J Heart Lung Transplant. 1993;12:173–8.PubMedGoogle Scholar
  26. 26.
    Weiss CI, Park JV, Bolman RM. Prostaglandin El for treatment of elevated pulmonary vascular resistance in patients undergoing cardiac transplantation. Transplant Proc. 1989;21:2555–6.PubMedGoogle Scholar
  27. 27.
    Semigran MJ, Cockrill BA, Kacmarek R et al, Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol. 1994;24:982–8.PubMedGoogle Scholar
  28. 28.
    Adatia I, Perry S. Landzberg M et al. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol. 1995;25:1656–64.PubMedCrossRefGoogle Scholar
  29. 29.
    Zales VR, Pahl E, Backer CL et al. Pharmacologic reduction of pretransplantation pulmonary vascular resistance predicts outcome after pediatric heart transplantation. J Heart Lung Transplant. 1993;12:965–73.PubMedGoogle Scholar
  30. 30.
    Kawaguchi A, Gandjbakhch I, Pavie A et al. Cardiac transplant recipients with preoperative pulmonary hypertension: evolution of pulmonary hemodynamics and surgical options. Circulation. 1989;80(Suppl. III):III–90–6.Google Scholar
  31. 31.
    Grant SCD, Levy RD, Brooks NH. Fall in pulmonary vascular resistance in patients awaiting heart transplantation. Br Heart J. 1992;68:365–8.PubMedGoogle Scholar
  32. 32.
    Boffa GM, Rezzonini R, Grassi G et al. Pulmonary vascular resistance variation over time in candidates for heart transplantation. Am J Cardiol. 1994;73:414–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Bhatia SJ, Kirshenbaum JM, Shemin RJ et al. Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Circulation. 1987;76:819–26.PubMedGoogle Scholar
  34. 34.
    Corcos T, Tamburino C, Leger P et al. Early and late hemodynamic evaluation after cardiac transplantation: a study of 28 cases. J Am Coll Cardiol. 1988;11:264–9.PubMedGoogle Scholar
  35. 35.
    von Scheidt W, Ziegler U. Kemkes BM, Erdman E. Heart transplantation; hemodynamics over a five-year period. J Heart Lung Transplant. 1991;10:342–50.Google Scholar
  36. 36.
    Costanzo-Nordin M, Liao Y, Grusk BB et al. Oversizing of donor hearts: beneficial or detrimental? J Heart Lung Transplant. 1991;10:717–30.PubMedGoogle Scholar
  37. 37.
    Yeoh T, Frist WH, Lagerstrom C et al. Relationship of cardiac allograft size and pulmonary vascular resistance to long-term cardiopulmonary function. J Heart Lung Transplant. 1992;11:1168–76.PubMedGoogle Scholar
  38. 38.
    Villanueva FS, Murali S, Uretsky BF et al. Resolution of severe pulmonary hypertension after heterotopic heart transplantation. J Am Coll Cardiol. 1989; 14:1239–43PubMedCrossRefGoogle Scholar
  39. 39.
    Naeije R, Lipski A, Abramowicz M et al. Nature of pulmonary hypertension in congestive heart failure. Am J Rcspir Crit Care Med. 1994;149:881–7.Google Scholar
  40. 40.
    Marti V, Ballester M, Auge JM et al. Donor and recipient determinants of fatal and nonfatal cardiac dysfunction during the first week after orthotopic heart transplantation. Transplant Proc. 1992;24:16–19.PubMedGoogle Scholar
  41. 41.
    Morley D, Brozena SC, Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am J Cardiol. 1994;73:379–83.PubMedCrossRefGoogle Scholar
  42. 42.
    Simonsen S. Molstad P, Geiran O, Froysaker T. Heart transplantation in patients with severe pulmonary hypertension and increased pulmonary vascular resistance. Scand J Thorac Cardiovasc Surg. 1990;24(3): 161–4.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • J. M. Chen
  • R. E. Michler

There are no affiliations available

Personalised recommendations